[en] Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy. This randomized, placebo-controlled, parallel-group study investigated the efficacy and tolerability of oral zolmitriptan (5, 10, 15 and 20 mg) in the treatment of single acute migraine attacks. Of 1181 patients randomized, 840 were evaluable for the primary efficacy analysis. Headache response rates (a reduction in headache intensity from severe or moderate at baseline to mild or no pain at 2 hours post-treatment) were similar across the zolmitriptan dose groups (66%, 71%, 69% and 77% for 5 mg, 10 mg, 15 mg and 20 mg, respectively) and were significantly higher than that for placebo (19%; all groups P < 0.001). A headache response was reported at 1 hour by 40-50% of zolmitriptan recipients (16% placebo). At 2 hours post dose, 39-47% of zolmitriptan-treated patients were pain-free, compared with 1% of placebo recipients. Headache recurrence occurred in 21-29% (upper 95% CI 37.1) of zolmitriptan-treated patients and in 65% (95% CI 38.3, 85.8) of placebo recipients. Zolmitriptan was well tolerated at each dose. The most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness. Most adverse events were of mild or moderate intensity and were transient. The frequency of adverse events was dose-related. Although, zolmitriptan 5 mg exhibited the most favourable efficacy and tolerability profile, the dose response data suggest that lower doses would also offer significant efficacy. Copyright 1998 Lippincott Williams & Wilkins
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Dahlof, C.
Diener, H. C.
Goadsby, P. J.
Massiou, H.
Olesen, J.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Wilkinson, M.
Sweet, R. M.
Klein, K. B.
Language :
English
Title :
Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study.
Dechant, K.L., Clissold, S.P., Sumatriptan: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of migraine and cluster headache (1992) Drugs, 43, pp. 776-798
Diener, H.C., A review of current treatments for migraine (1994) European Neurology, 34 (2 SUPPL.), pp. 18-25
Diener, H.C., Klein, K.B., The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine (1996) Functional Neurology, 11, p. 152. , abstract 24b and poster presented at the 3rd European Headache Conference 5-8 June, Sardinia
Dixon, R., Warrander, A., The clinical pharmacokinetics of zolmitriptan (1997) Cephalalgia, 17 (18 SUPPL.), pp. 15-20
Edmeads, J., Millson, D.S., Tolerability profile of zolmitriptan (Zomig™
311C90), a novel dual central and peripheral 5HT1B/1D agonist (1997) Cephalalgia, 17 (18 SUPPL.), pp. 41-52
Goadsby, P.J., Edvinsson, L., Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90 (1994) Headache, 34, pp. 394-399
Goadsby, P.J., Hoskin, K.J.L., Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic targets in migraine? (1996) Pain, 67, pp. 355-359
Goadsby, P., Olesen, J., Diagnosis and management of migraine (1996) British Medical Journal, 312, pp. 1279-1283
Goadsby, P.J., Knight, Y.E., Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in the cat (1997) Cephalalgia, 17, pp. 153-158
Göbel, H., Petersen-Braun, M., Heinze, A., Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? (1997) Frontiers in Headache Research, Vol. 6, Headache Treatment. Trial Methodology and New Drugs, 6, pp. 93-98. , (Eds J Olesen and P Tfelt-Hansen), Philadelphia, Lippincott-Raven
Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain (1988) Cephalalgia, 8 (7 SUPPL.), pp. 1-96
Martin, G., Pre-clinical pharmacology of zolmitriptan (Zomig™, formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine (1997) Cephalalgia, 17 (18 SUPPL.), pp. 4-14
Martin, G.R., Robertson, A.D., MacLennan, S.J., Prentice, D.J., Barrett, V.J., Honey, A.C., Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D partial agonist, 311C90 (zolmitriptan) (1997) British Journal of Pharmacology, 121, pp. 157-164
Mathew, N., Serotonin1D (5-HT1D) agonists and other agents in acute migraine (1997) Neurologic Clinics, 15, pp. 61-83
Osterhaus, J.T., Gutterman, D.L., Plachet, K.A., Healthcare resource and lost labour costs of migraine headache in the US (1992) Pharmacoeconomics, 2, pp. 67-76
Proietti-Cecchini, A., Áfra, J., Schoenen, J., Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of CNS serotonin transmission in man: Demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig™) (1997) Cephalalgia, 17, pp. 849-854
Rapoport, A.M., Ramadan, N.M., Adelman, J.U., Mathew, N.T., Elkind, A.H., Kudrow, D.B., Earl, N., Optimizing the dose of zolmitriptan ('Zornig', 311C90) in the acute treatment of migraine (1997) Neurology, 49, pp. 1210-1218
Rasmussen, B.K., Epidemiology of headache (1995) Cephalalgia, 15, pp. 45-68
Schoenen, J., Sawyer, J., Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy (1997) Cephalalgia, 17 (18 SUPPL.), pp. 28-40
Schoenen, J., Klein, K.B., Sweet, R.M., The CNS adverse event profiles of 311C90 and sumatriptan appear identical (1996) European Journal of Neurology, 3 (5 SUPPL.), p. 153. , abs 410 and poster presented at the 2nd Congress of the European Federation of Neurological Sciences, Rome
Simmons, V.E., Blakeborough, P., The safety profile of sumatriptan (1994) Reviews in Contemporary Pharmacotherapy, 5, pp. 319-328
Stewart, W.F., Lipton, R.B., Celentano, D.D., Reed, M.L., Prevalence of migraine headache in the United States (1992) Journal of the American Medical Association, 267, pp. 64-69
Storer, R.J., Goadsby, P.J., Microiontophoretic application of serotonin (5HT)-1B/1D agonists inhibits trigeminal cell firing in the cat (1998) Brain, , in press
Visser, W.H., Ferrari, M.D., Klein, K.B., Cox, R.C., Jones, D., An in-patient, placebo-controlled, dose-ranging study of oral zolmitriptan in the acute treatment of migraine (1996) Neurology, 46, pp. 522-526
Visser, W.H., Terwindt, G.M., Reines, S.A., Jiang, K., Lines, C.R., Ferrari, M.D., Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study (1996) Archives of Neurology, 53, pp. 1132-1137
Zagami, A.S., 31IC90: Long-term efficacy and tolerability profile for the acute treatment of migraine (1997) Neurology, 48 (3 SUPPL.), pp. S25-28